Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.


CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1.


Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.

Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C, Umaña P, Benincosa L, Bachl J, Singer T, Bray-French K.

J Immunother. 2016 Sep;39(7):279-89. doi: 10.1097/CJI.0000000000000132.


In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.

Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M.

Clin Cancer Res. 2016 Sep 1;22(17):4417-27. doi: 10.1158/1078-0432.CCR-15-2622. Epub 2016 Apr 26.


A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P.

Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9.


Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.

Anghel SI, Correa-Rocha R, Budinska E, Boligan KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V.

Pigment Cell Melanoma Res. 2012 Jul;25(4):482-7. doi: 10.1111/j.1755-148X.2012.01018.x. Erratum in: Pigment Cell Melanoma Res. 2012 Nov;25(6):834. Correa-Rochal, Rafael [corrected to Correa-Rocha, Rafael]; Boliganl, Kayluz F [corrected to Boligan, Kayluz F].


Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation.

Tomasoni R, Basso V, Pilipow K, Sitia G, Saccani S, Agresti A, Mietton F, Natoli G, Colombetti S, Mondino A.

Eur J Immunol. 2011 Jul;41(7):2086-96. doi: 10.1002/eji.201041130.


IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector.

Colombetti S, Lévy F, Chapatte L.

Blood. 2009 Jun 25;113(26):6629-37. doi: 10.1182/blood-2008-05-155309. Epub 2009 Apr 21.


Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.

Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, Alves P, Ritter G, Ayyoub M, Valmori D, Chen W, Lévy F.

Eur J Immunol. 2008 Jul;38(7):1867-76. doi: 10.1002/eji.200737923.


Promises and limitations of murine models in the development of anticancer T-cell vaccines.

Lévy F, Colombetti S.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):269-95. Review.


Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.

Colombetti S, Fagerberg T, Baumgärtner P, Chapatte L, Speiser DE, Rufer N, Michielin O, Lévy F.

J Immunol. 2006 Jun 1;176(11):6560-7.


Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.

Chapatte L, Colombetti S, Cerottini JC, Lévy F.

Cancer Res. 2006 Jan 15;66(2):1155-60.


Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation.

Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME.

J Cell Biol. 2004 Feb 2;164(3):441-9. Epub 2004 Jan 26.


Clonal anergy is maintained independently of T cell proliferation.

Colombetti S, Benigni F, Basso V, Mondino A.

J Immunol. 2002 Dec 1;169(11):6178-86.


Constitutive active p21ras enhances primary T cell responsiveness to Ca2+ signals without interfering with the induction of clonal anergy.

Crespi D, Massa S, Basso V, Colombetti S, Mueller DL, Mondino A.

Eur J Immunol. 2002 Sep;32(9):2500-9.


Xotx5b, a new member of the Otx gene family, may be involved in anterior and eye development in Xenopus laevis.

Vignali R, Colombetti S, Lupo G, Zhang W, Stachel S, Harland RM, Barsacchi G.

Mech Dev. 2000 Aug;96(1):3-13.

Supplemental Content

Loading ...
Support Center